ST STZ Constellation Brands Loading... : Bullish and Bearish Analyst Opinions

Constellation Brands faces structural alcohol decline

Constellation Brands announces a 100 million dollar investment in U.S.

Berkshire Hathaway's Q2 portfolio update reveals new positions in D.R.

STZ is best US alcohol expression.

Health optimization has peaked; buy alcohol stocks.

Beer brands strong, stock cheap

The World Cup had a limited impact on the overall U.S. category, with the notable exception of on-premise channels in host cities, where the company saw 14% growth. — Highlights that major sporting events primarily benefit on-premise venues in host cities, not the broader category, which has implications for how beer companies allocate marketing spend.

US beer weak, global beer strong

Constellation Brands a steal after sell-off.

Beer earnings bottom, bargain steal

BofA trimmed STZ; consumer spending rotation from goods to experiences (travel over staples).

Morgan Stanley cuts Constellation Brands PT to $158.

Seeking Alpha reports Constellation Brands' mixed earnings with beer growth offsetting.

Pre-market movers report shows Shutterstock plunging 32% on merger termination.

Shares a news article about beer demand ahead of the World Cup.

Alcohol stocks are bottoming, buy now.

The tweet notes that several alcoholic beverage companies like STZ, BFb.

Constellation Brands is a buy as alcohol bottoms.

Cramer said he is "excited about the possibilities" for Constellation Brands, believes its new CEO can revitalize the business, and sees a "subtle turn in beer and a definite turn in the ready to drink cocktail market." He concluded, "STZ, I think it might be worth even buying ahead." The company owns the top beer in the country (Modelo). He believes the headwinds in liquor are known, but an improving trend in its core beer and RTD segments under new leadership makes the stock attractive. The stock is a buy based on a potential turnaround and positive secular shifts in its key markets. The turn in consumer trends does not materialize, or GLP-1 drug impact on alcohol consumption is more severe than anticipated.

Rogers states, "Americans no longer are drinking alcohol the way they used to." A secular decline in alcohol consumption (health trends, GLP-1 drugs) makes the "moat" of beer and spirits companies structurally weaker. They are value traps. AVOID Alcohol/Spirits stocks. International growth offsets US decline.

"I'm looking at, for instance, LVMH, Moet Hennessy in Europe, climbing on the news, up 4.4%... companies that rely on exports to the U.S. also benefiting." The ruling specifically removes threats on "French wine" and other foreign goods. European luxury and beverage companies regain price competitiveness in the US market without the artificial tax wedge. LONG European Exporters, specifically Luxury and Spirits. Retaliatory measures from the US administration using different legal frameworks (e.g., National Security grounds).

Spevak observes a major demographic shift: "Everybody knows drinking is way down." Young people want to be in bed by 11 PM to hit the gym the next morning rather than partying late. The "high-performance lifestyle" is fundamentally incompatible with heavy alcohol consumption. As health/longevity becomes the ultimate status symbol, alcohol volume (especially among high-net-worth individuals and youth) faces a secular headwind. Avoid major alcohol producers as social habits shift toward wellness and recovery. Alcohol companies successfully pivoting to non-alcoholic beverages (which they are attempting).

Guidance for FY26 maintained despite macro headwinds, but beer margin trajectory for FY27-28 will be reassessed in April; tone is cautious but not deteriorating.

Management attributes weakness to cyclical socioeconomic factors (Hispanic consumer sentiment, macro uncertainty) rather than structural category decline, but acknowledges unprecedented volatility and mixed results, leading to a cautious but not panicked tone.